Mostrar el registro sencillo del ítem
dc.contributor.author | Fernandez-Delgado, Irene | |
dc.contributor.author | Calzada-Fraile, Diego | |
dc.contributor.author | Sanchez-Madrid, Francisco | |
dc.date.accessioned | 2021-06-29T08:44:21Z | |
dc.date.available | 2021-06-29T08:44:21Z | |
dc.date.issued | 2020-11-28 | |
dc.identifier.citation | Cancers (Basel). 2020; 12(12):e3558 | es_ES |
dc.identifier.issn | 2072-6694 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/13207 | |
dc.description.abstract | Extracellular vesicles (EVs) play a crucial role in intercellular communication as vehicles for the transport of membrane and cytosolic proteins, lipids, and nucleic acids including different RNAs. Dendritic cells (DCs)-derived EVs (DEVs), albeit variably, express major histocompatibility complex (MHC)-peptide complexes and co-stimulatory molecules on their surface that enable the interaction with other immune cells such as CD8+ T cells, and other ligands that stimulate natural killer (NK) cells, thereby instructing tumor rejection, and counteracting immune-suppressive tumor microenvironment. Malignant cells oppose this effect by secreting EVs bearing a variety of molecules that block DCs function. For instance, tumor-derived EVs (TDEVs) can impair myeloid cell differentiation resulting in myeloid-derived suppressor cells (MDSCs) generation. Hence, the unique composition of EVs makes them suitable candidates for the development of new cancer treatment approaches including prophylactic vaccine targeting oncogenic pathogens, cancer vaccines, and cancer immunotherapeutics. We offer a perspective from both cell sides, DCs, and tumor cells, on how EVs regulate the antitumor immune response, and how this translates into promising therapeutic options by reviewing the latest advancement in DEV-based cancer therapeutics. | es_ES |
dc.description.sponsorship | This work was supported by grant SAF2017-82886-R from the Spanish Ministry of Economy and Competitiveness (MINECO), grant S2017/BMD-3671-INFLAMUNE-CM from the Comunidad de Madrid, a grant from the Ramón Areces Foundation “Ciencias de la Vida y la Salud” (XIX Concurso-2018) and a grant from Ayudas Fundación BBVA a Equipos de Investigación Científica (BIOMEDICINA-2018), the Fundació Marató TV3 (grant 122/C/2015) and “La Caixa” Banking Foundation (HR17-00016). BIOIMID (PIE13/041) from Instituto de Salud Carlos III, CIBER Cardiovascular (CB16/11/00272, Fondo de Investigación Sanitaria del Instituto de Salud Carlos III and co-funding by Fondo Europeo de Desarrollo Regional FEDER). D.C.-F. is supported by a Fellowship from “la Caixa” Foundation (LCF/BQ/DR19/11740010). I.F.-D. is supported by a Fellowship from Spanish Ministry of Science, Innovation and Universities (FPU15/02539). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.title | Immune Regulation by Dendritic Cell Extracellular Vesicles in Cancer Immunotherapy and Vaccines. | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 33260499 | es_ES |
dc.format.volume | 12 | es_ES |
dc.format.number | 12 | es_ES |
dc.format.page | e3558 | es_ES |
dc.identifier.doi | 10.3390/cancers12123558 | es_ES |
dc.contributor.funder | Ministerio de Economía y Competitividad (España) | |
dc.contributor.funder | Comunidad de Madrid (España) | |
dc.contributor.funder | Fundación Ramón Areces | |
dc.contributor.funder | Fundación BBVA | |
dc.contributor.funder | Fundación La Marató TV3 | |
dc.contributor.funder | Fundación La Caixa | |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | |
dc.contributor.funder | Ministerio de Ciencia, Innovación y Universidades (España) | |
dc.contributor.funder | Ministerio de Ciencia e Innovación (España) | |
dc.description.peerreviewed | No | es_ES |
dc.relation.publisherversion | https://doi.org/10.3390/cancers12123558 | es_ES |
dc.identifier.journal | Cancers | es_ES |
dc.repisalud.orgCNIC | CNIC::Grupos de investigación::Comunicación Intercelular en la Respuesta Inflamatoria | es_ES |
dc.repisalud.institucion | CNIC | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/SAF2017-82886-R | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/S2017/BMD-3671-INFLAMUNE-CM | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/22/C/2015 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/HR17-00016 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PIE13/041 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/CB16/11/00272 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/LCF/BQ/DR19/11740010 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/FPU15/02539 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/SEV-2015-0505 | es_ES |